Marketing Authorization Applications, Financial Results, Product Up-gradations, and Presentations - Research Report on Baxter, Seattle Genetics, IDEXX, Hill-Rom, and BioCryst
NEW YORK, November 8, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Seattle Genetics Inc. (NASDAQ: SGEN), IDEXX Laboratories, Inc. (NASDAQ: IDXX), Hill-Rom Holdings, Inc. (NYSE: HRC), and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Baxter International Inc. Research Report
On October 31, 2013, Baxter International Inc. (Baxter) announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of RIXUBIS, recombinant factor IX (nonacog gamma) for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B. The Company informed that filing is based on results of research with hemophilia B patients previously treated with other therapies along with supportive data from a study of 23 hemophilia B patients less than twelve years old. According to Baxter, RIXUBIS was approved for adult patients and launched in the United States and Puerto Rico earlier 2013. Anders Ullman, M.D., Ph.D., Vice President of Global Research and Development in Baxter's BioScience business, stated, "Our focus at Baxter is to strengthen and expand the portfolio of treatments for patients with bleeding disorders, particularly when there are limited treatment options, such as for patients with hemophilia B." Ullman continued, "We are actively working to extend access to these treatments and look forward to introducing RIXUBIS in Europe and other countries around the world." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/163d_BAX]
--
Seattle Genetics Inc. Research Report
On November 5, 2013, Seattle Genetics Inc. (Seattle Genetics) released its Q3 2013 results. Seattle Genetics registered total revenues of $71 million in Q3 2013, up 42.4% YoY. The Company posted net loss of $23.7 million or $0.19 per diluted share in Q3 2013, compared to net loss of $13.7 million or $0.12 per diluted share in Q3 2012. Commenting on the results, Clay B. Siegall, Ph.D., President and CEO of Seattle Genetics, said, "We ended the third quarter in a strong financial position, driven by ADCETRIS net sales and collaboration revenues, leading us to increase our full year 2013 guidance in both areas. We expect several milestones over the remainder of the year, notably reporting data from multiple abstracts at the ASH annual meeting in December and advancing an additional ADC into clinical trials." The Full Research Report on Seattle Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ff98_SGEN]
--
IDEXX Laboratories, Inc. Research Report
On November 5, 2013, IDEXX Laboratories, Inc. (IDEXX) announced the addition of fructosamine testing to its unparalleled test menu for the Catalyst Dx Chemistry Analyzer to help veterinarians better manage diabetic patients. Tina Hunt, Director at IDEXX VetLab Chemistry, explained, "Many veterinarians over the years have asked IDEXX to develop an accurate and affordable point- of-care fructosamine test." Hunt added, "We're now pleased to fulfill this request with the new fructosamine slide for the Catalyst Dx Chemistry Analyzer, which provides accurate results in less than 9 minutes. When assessed with blood glucose levels, the veterinarian is now able to modify insulin therapy, educate clients and address any questions or concerns, all within the appointment time frame." The Full Research Report on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/bf62_IDXX]
--
Hill-Rom Holdings, Inc. Research Report
On November 5, 2013, Hill-Rom Holdings, Inc. (Hill-Rom) announced that its management will represent the Company at the 2013 Credit Suisse Annual Healthcare Conference on Wednesday, November 13, 2013, at 12:00 p.m. EST. Hill-Rom informed that interested parties can listen to the live discussion of the conference through its Investor Relations website or may access a replay of the same an hour after the completion of the presentation until November 27, 2013. The Full Research Report on Hill-Rom Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/777e_HRC]
--
BioCryst Pharmaceuticals, Inc. Research Report
On November 5, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) released its Q3 2013 results. BioCryst registered total revenues of $2.4 million in Q3 2013, compared to total revenues of $5.8 million in Q3 2012. The Company posted net loss of $8.0 million or $0.14 per diluted common share in Q3 2013, compared to net loss of $9.7 million or $0.19 per diluted common share in Q3 2012. Jon P. Stonehouse, President and CEO of BioCryst, stated, "Throughout 2013, we have continued to make progress and create value in our core development programs, while we prudently managed our operations with financial discipline. Our recent accomplishments include the initiation of patient screening for the Phase 2a proof of concept clinical trial of BCX4161 for HAE and securing government funding for the development of BCX4430 as a potential treatment for Marburg virus disease." Stonehouse added, "Furthermore, our regulatory team is working towards a goal of submitting the peramivir NDA filing by the end of 2013 in order to make peramivir available to influenza patients in the 2014-15 Northern Hemisphere flu season." The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/f9b1_BCRX]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article